Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
AiVita, allergic, ALPHAEON, anniversary, ASC, Asia, assisting, automatically, beta, Biomedical, budget, calendar, called, Cardio, CDMO, Chemical, cleared, cohort, CompanyTM, comply, compounded, conglomerate, curative, deep, deliver, dermatological, diagnosed, diversification, driven, durability, earliest, Employee, enterprise, EU, Europe, exclusive, Family, feasibility, franchise, gene, global, government, grace, group, guidance, hematopoietic, Hitachi, immunological, implied, independent, independently, India, insulin, intercompany, Lastly, lessee, lifelong, lump, maintain, man, margin, membership, mezzanine, monitoring, NASDAW, newly, notable, Notably, noteworthy, notification, notify, notifying, occasion, pathway, pediatric, pivotal, PMDA, post, practice, priority, prompt, publicly, Put, redeemable, redemption, regain, repay, replacement, restructuring, retain, retaining, select, selected, SPS, subordinated, symbol, TID, tolerance, training, underpinned, undertaken, Union, unmet, writing
Removed:
abandonment, accredited, actively, adequately, advanced, advancement, advertising, Advisor, advisory, aging, allocate, allocated, allocation, AMI, Amorcyte, amortize, announced, antigen, approximate, arising, assigned, assumed, bad, began, BLA, blood, brain, canceled, cancer, capability, challenging, charged, CHF, colon, commonly, comprehensive, concentration, consultation, consummated, continuation, converted, CSC, cycle, dated, death, decline, Defense, derivative, derived, designation, deteriorate, deterioration, developed, direct, disclose, doubt, earlier, earn, economic, elevation, EMA, employed, enhance, establish, establishing, exemption, expedited, Fast, forma, formation, fourth, fractional, funding, harmonize, health, higher, highly, identification, imminent, implementing, improve, increased, indefinite, infringement, initiating, initiation, Institute, integrated, intent, invoice, involving, issue, Jason, lattice, leader, letter, leveraging, lieu, likelihood, liquid, liquidation, liver, Livingston, local, lung, made, malignant, marketing, Measuring, Medicinal, merged, mortgage, National, nominal, obligation, obtaining, offer, Orphan, ovarian, oxygen, oxygenated, paradigm, patent, path, periodically, personal, plan, point, positioning, preferred, preparing, presentation, presumption, pro, profit, progression, promulgated, purified, qualifying, randomization, randomizing, real, realized, Recognizing, recouped, recover, recovery, recurrent, reducing, reduction, reflected, regenerate, registered, regularly, relevant, reliable, reliance, remeasurement, repaid, represent, representative, reserve, resold, response, resulting, revalued, review, royalty, screening, segment, settlement, show, significantly, similar, solicitation, source, SPA, Specifically, ST, stated, STEMI, step, strong, studied, Subco, subjectivity, sublicensing, substantial, Subtopic, succeeded, supplemental, supported, surviving, Track, underlying, unexercised, unique, unrealized, updated, variable, weakening, wholly
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 4.1 Exhibit 4.1 Form of Warrant
- 10.1 Exhibit 10.1 Upa
- 10.2 Exhibit 10.2 Operating Agreement
- 10.3 Exhibit 10.3 Tech Lic*
- 10.4 Exhibit 10.4 Preti CLBS
- 10.5 Exhibit 10.5 Preti PCT
- 10.6 Exhibit 10.6 Oxford Third
- 10.7 Exhibit 10.7 Spa
- 10.8 Exhibit 10.8 Rra
- 31.1 Exhibit 31.1 Mazzo
- 31.2 Exhibit 31.2
- 32.1 Exhibit 32.1
- 32.2 Exhibit 32.2
- Download Excel data file
- View Excel data file
LSTA similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Caladrius Biosciences, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2016 filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph Talamo, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented. |
Dated: May 5, 2016
/s/ Joseph Talamo | |
Joseph Talamo | |
Senior Vice President and Chief Financial Officer |
The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.
A signed original of this written statement required by Section 906 has been provided to Caladrius Biosciences, Inc. and will be retained by Caladrius Biosciences, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.